Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Liabilities and Shareholders Equity: 2013-2025

Historic Liabilities and Shareholders Equity for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $415.5 million.

  • Theravance Biopharma's Liabilities and Shareholders Equity rose 16.67% to $415.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 4.61%. This contributed to the annual value of $354.2 million for FY2024, which is 7.29% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Liabilities and Shareholders Equity is $415.5 million, which was down 2.48% from $426.0 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Liabilities and Shareholders Equity high stood at $763.5 million for Q3 2022, and its period low was $343.6 million during Q1 2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $382.0 million (2023), whereas its average is $400.9 million.
  • Per our database at Business Quant, Theravance Biopharma's Liabilities and Shareholders Equity skyrocketed by 89.40% in 2022 and then plummeted by 45.83% in 2023.
  • Over the past 5 years, Theravance Biopharma's Liabilities and Shareholders Equity (Quarterly) stood at $374.8 million in 2021, then spiked by 62.05% to $607.4 million in 2022, then tumbled by 37.11% to $382.0 million in 2023, then decreased by 7.29% to $354.2 million in 2024, then grew by 16.67% to $415.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $415.5 million for Q3 2025, versus $426.0 million for Q2 2025 and $343.6 million for Q1 2025.